1-3 of 3
Daniel Molin
Close
Sort by
Journal Articles

Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy–treated mantle cell lymphoma

Anna Nikkarinen, Lavanya Lokhande, Rose-Marie Amini, Mats Jerkeman, Anna Porwit, Daniel Molin, Gunilla Enblad, Arne Kolstad, Riikka Räty, Martin Hutchings, Caroline E. Weibull, Peter Hollander, Sara Ek, Ingrid Glimelius
Journal: Blood Advances
Blood Adv (2023) 7 (18): 5304–5313.
https://doi.org/10.1182/bloodadvances.2023010052
Published: 2023
Includes: Supplemental data
Journal Articles

Revisiting IL-6 expression in the tumor microenvironment of classical Hodgkin lymphoma

Alex Reza Gholiha, Peter Hollander, Ingrid Glimelius, Gustaf Hedstrom, Daniel Molin, Henrik Hjalgrim, Karin E. Smedby, Jamileh Hashemi, Rose-Marie Amini, Gunilla Enblad
Journal: Blood Advances
Blood Adv (2021) 5 (6): 1671–1681.
https://doi.org/10.1182/bloodadvances.2020003664
Published: 2021
Includes: Supplemental data
Journal Articles

High proportions of PD-1 + and PD-L1 + leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome

Clinical Trials & Observations
Peter Hollander, Peter Kamper, Karin Ekstrom Smedby, Gunilla Enblad, Maja Ludvigsen, Julie Mortensen, Rose-Marie Amini, Stephen Hamilton-Dutoit, Francesco d’Amore, Daniel Molin, Ingrid Glimelius
Journal: Blood Advances
Blood Adv (2017) 1 (18): 1427–1439.
https://doi.org/10.1182/bloodadvances.2017006346
Published: 2017
Includes: Supplemental data